Table 1.
Percent steatosis, lobular and non-alcoholic fatty liver disease activity score were reduced due to combination therapy
| HCD (n = 9) | HCD + Cu (n = 9) | HCD + VE (n = 7) | HCD + Cu + VE (n = 9) | |
| Histology diagnosis | NASH (9) | Steatosis (2)/NASH (7) | Steatosis (2)/NASH (5) | Steatosis (4)/NASH (5) |
| Steatosis grade | 3 (3-3) | 3 (2-3) | 3 (2-3) | 3 (2-3) |
| % steatosis | 95 (80-100) | 80 (40-100) | 95 (70-100) | 75 (40-95)a |
| Lobular score | 2 (1-2) | 2 (1-3) | 1 (0-2) | 1 (0-3) |
| Ballooning | 2 (1-2) | 2 (1-2) | 1 (1-2) | 1 (0-2) |
| NAS score | 6 (5-7) | 6 (4-8) | 6 (4-6) | 5 (3-8) |
| Fibrosis stage | 1a (0-1a) | 0 (0-1a) | 0 (0-1a) | 0 (0-1a) |
Values are expressed as the median (range).
a
P < 0.05 vs HCD alone, Kruskal-Wallis ANOVA. HCD: High calorie diet; Cu: Curcumin; VE: Vitamin E; NAS: Non-alcoholic fatty liver disease activity score.